Gleave M - Search Results

1

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M. Yamamoto Y, et al. Among authors: gleave m. Clin Cancer Res. 2015 Apr 1;21(7):1675-87. doi: 10.1158/1078-0432.CCR-14-1108. Epub 2015 Jan 29. Clin Cancer Res. 2015. PMID: 25634993

2

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Gleave ME, et al. Cancer Res. 1992 Mar 15;52(6):1598-605. Cancer Res. 1992. PMID: 1371718

3

Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.

Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Gleave M, et al. Cancer Res. 1991 Jul 15;51(14):3753-61. Cancer Res. 1991. PMID: 1712249

4

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: gleave me. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

5

Differential transactivation by the androgen receptor in prostate cancer cells.

Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Snoek R, et al. Among authors: gleave m. Prostate. 1998 Sep 1;36(4):256-63. doi: 10.1002/(sici)1097-0045(19980901)36:4<256::aid-pros7>3.0.co;2-d. Prostate. 1998. PMID: 9719026

6

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

Miyake H, Tolcher A, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 1999 Aug 15;59(16):4030-4. Cancer Res. 1999. PMID: 10463603

7

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Gleave M, et al. Clin Cancer Res. 1999 Oct;5(10):2891-8. Clin Cancer Res. 1999. PMID: 10537358

8

Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.

Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Gleave ME, et al. Urology. 1999 Dec;54(6A Suppl):36-46. doi: 10.1016/s0090-4295(99)00453-7. Urology. 1999. PMID: 10606283

9

Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.

Miayake H, Tolcher A, Gleave ME. Miayake H, et al. Among authors: gleave me. J Natl Cancer Inst. 2000 Jan 5;92(1):34-41. doi: 10.1093/jnci/92.1.34. J Natl Cancer Inst. 2000. PMID: 10620631

10

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

Miyake H, Nelson C, Rennie PS, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 Jan 1;60(1):170-6. Cancer Res. 2000. PMID: 10646870

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

692 results

Search Page

Filters